Review on emu products for use as complementary and alternative medicine

Nutrition

Volumn 31, Issue 1, 2015, Pages 21-27

  Jeengar, Manish Kumar ^a   Sravan Kumar, P ^a   Thummuri, Dinesh ^a   Shrivastava, Shweta ^a   Guntuku, Lalita ^a   Sistla, Ramakrishna ^b   Naidu, V G M ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Antioxidant; Emu oil; GPR120; Inflammation; MUFA; Penetration enhancer; PUFAs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; COSMETIC; CURCUMIN; EMU OIL; G PROTEIN COUPLED RECEPTOR 120; GAMMA LINOLENIC ACID; IBUPROFEN; INSECT REPELLENT; INSULIN; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN; NATURAL PRODUCT; OLEIC ACID; OMEGA 3 FATTY ACID; PENETRATION ENHANCING AGENT; POLYUNSATURATED FATTY ACID; PROGESTERONE; UNCLASSIFIED DRUG; ANTIOXIDANT; OIL; UNSATURATED FATTY ACID;

ADJUVANT ARTHRITIS; ALOPECIA; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOATING; BURN; CANCER CHEMOTHERAPY; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET SUPPLEMENTATION; DROMAIUS NOVAEHALLANDIAE; DRUG BIOAVAILABILITY; EGG; HAIR GROWTH; HOT FLUSH; HUMAN; HYPOPIGMENTATION; INFLAMMATORY BOWEL DISEASE; INSULIN RESISTANCE; LIBIDO DISORDER; MALE TYPE ALOPECIA; MEAT; MELANOGENESIS; MENOPAUSAL SYNDROME; MENTAL INSTABILITY; MUCOSA INFLAMMATION; NANOEMULSION; NONHUMAN; NUTRITIONAL VALUE; OSTEOPENIA; OSTEOPOROSIS; OTITIS; PREMENSTRUAL SYNDROME; PSORIASIS; RATITE; REVIEW; SHELF LIFE; SKIN PENETRATION; VAGINAL DRYNESS; WOUND HEALING; ANIMAL; AUSTRALIA; DROMAIIDAE; INFLAMMATION;

DROMAIUS; HEXAPODA; PALAEOGNATHAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AUSTRALIA; COMPLEMENTARY THERAPIES; DROMAIIDAE; EGGS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; MEAT; OILS;

EID: 84920906729     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.04.004     Document Type: Review

References (51)

1. Angel C.R. A review of ratite nutrition. Anim Feed Sci Technol 1996, 60:241-246.
2. Whitehouse M.W., Turner A.G., Davis C.K.C., Roberts M.S. Emu oil (s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. Inflammopharmacology 1998, 6:1-8.
3. Davies S. Emus. Australian Natural History 1963, 14:225-229.
4. Sales J. The emu (Dromaius novaehollandiae): a review of its biology and commercial products. Avian Biol Res 2007, 18:1-20.
5. Sales J., Horbanczuk J. Ratite meat. Worlds Poult Sci J 1998, 54:59-68.
6. Pegg R.B., Amarowicz R., Code W.E. Nutritional characteristics of emu (Dromaius novaehollandiae) meat and its value-added products. Food Chem 2006, 97:193-202.
7. Wang Y.W., Sunwoo H., Sim J.S., Cherian G. Lipid characteristics of emu meat and tissues. J Food Lipids 2000, 7:71-82.
8. Suman S.P., Joseph P., Li S., Beach C.M., Fontaine M., Steinke L. Amino acid sequence of myoglobin from emu (Dromaius novaehollandiae) skeletal muscle. Meat Sci 2010, 86:623-628.
9. Beckerbauer L.M., Thiel-Cooper R., Ahn D.U., Sell J.L., Parrish F.C., Beitz D.C. Influence of two dietary fats on the composition of emu oil and meat. Poult Sci 2001, 80:187-194.
10. Caputo J, Fein E, Nagal K-L, Nagal AK. Therapeutic uses of emu oil. Google Patents;1995.
11. Bennett D.C., Code W.E., Godin D.V., Cheng K.M. Comparison of the antioxidant properties of emu oil with other avian oils. Anim Prod Sci 2008, 48:1345-1350.
12. Snowden J.M., Whitehouse M.W. Anti-inflammatory activity of emu oils in rats. Inflammopharmacology 1997, 5:127-132.
13. Kaki S.S., Ravinder T., Rao B.V.S.K., Chakrabarti P.P., Prasad R.B.N. Isolation and characterization of oil from fatty tissues of emu birds farmed in India. J Lipid Sci Technol 2013, 45:13-19.
14. Abimosleh Suzanne M., Tran Cuong D., Howarth Gordon S. Emu oil reduces small intestinal inflammation in the absence of clinical improvement in a rat model of indomethacin-induced enteropathy. Evid Based Complement Alternat Med 2013, 2013:429706.
15. Abimosleh S.M., Tran C.D., Howarth G.S. Emu oil: a novel therapeutic for disorders of the gastrointestinal tract?. J Gastroenterol Hepatol 2012, 27:857-861.
16. Stringer A.M., Gibson R.J., Bowen J.M., Logan R.M., Yeoh A.S., Keefe D.M. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007, 5:259-267.
17. Lalla R.V., Peterson D.E. Treatment of mucositis, including new medications. Cancer J 2006, 12:348-354.
18. Gibson R.J., Keefe D.M.K., Lalla R.V., Bateman E., Blijlevens N., Fijlstra M., et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013, 21:313-326.
19. Gibson R.J., Keefe D.M., Clarke J.M., Regester G.O., Thompson F.M., Goland G.J., et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002, 50:53-58.
20. Cool J.C., Dyer J.L., Xian C.J., Butler R.N., Geier M.S., Howarth G.S. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 2005, 15:72-82.
21. Tran C.D., Howarth G.S., Coyle P., Philcox J.C., Rofe A.M., Butler R.N. Dietary supplementation with zinc and a growth factor extract derived from bovine cheese whey improves methotrexate-damaged rat intestine. Am J Clin Nutr 2003, 77:1296-1303.
22. Gibson R.J., Stringer A.M., Bowen J.M., Logan R.M., Yeoh A.S., Burns J., et al. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007, 6:541.
23. Lindsay R.J., Geier M.S., Yazbeck R., Butler R.N., Howarth G.S. Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr 2010, 104:513.
24. Carter M.J., Lobo A.J., Travis S.P.L. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004, 53:v1-v16.
25. Abimosleh S.M., Lindsay R.J., Butler R.N., Cummins A.G., Howarth G.S. Emu oil increases colonic crypt depth in a rat model of ulcerative colitis. Dig Dis Sci 2012, 57:887-896.
26. Yoganathan S., Nicolosi R., Wilson T., Handelman G., Scollin P., Tao R., et al. Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 2003, 38:603-607.
27. Xian C.J., Cool J.C., Scherer M.A., Macsai C.E., Fan C., Covino M., et al. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 2007, 41:842-850.
28. Xian C.J., Cool J.C., van Gangelen J., Foster B.K., Howarth G.S. Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. Cancer Biol Ther 2007, 6:170-177.
29. Raghu Nadhanan R., Abimosleh S.M., Su Y.-W., Scherer M.A., Howarth G.S., Xian C.J. Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss. Am J Physiol Gastrointest Liver Physiol 2012, 302:E1440-E1449.
30. Wilson T.A., Nicolosi R.J., Handelman G., Yoganathan S., Kotyla T., Orthoefer F., et al. Comparative effects of emu and olive oil on aortic early atherosclerosis and associated risk factors in hypercholesterolemic hamsters. Nutr Res 2004, 24:395-406.
31. Fukushima M., Ohashi T., Sekikawa M., Nakano M. Comparative hypocholesterolemic effects of five animal oils in cholesterol-fed rats. Biosci Biotechnol Biochem 1999, 63:202-205.
32. Holick MF. Use of emu oil for stimulating skin and hair growth. Google Patents;1999.
33. Zemstov A., Gaddis M., Montalvoa-Lugo V.M. Moisturizing and cosmetic properties of emu oil: A pilot double blind study. Australas J Dermatol 1996, 37:159-162.
34. Tisdale CJ, Zemtsov A. Creams and lotions containing emu oil. Google Patents;2000.
35. Nelson AH. Administering progesterone using EMU oil. Google Patents;2001.
36. Van Engelen HW, Van Engelen PA. Topical dermal anaesthetic. Google Patents;2002.
37. Pearson M, Barr TL. EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic. Google Patents;2003.
38. Farmer S. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations. Google Patents;2003.
39. Akram M., Naqvi S.B.S., Khan A. Design and development of insulin emulgel formulation for transdermal drug delivery and its evaluation. Pak J Pharm Sci 2013, 26:323-332.
40. Marrone PG, Judd SA. Method of using EMU oil as an insect repellent. Google Patents;1997.
41. Lagniel C., Torres A.M. Consequences of burn injuries treatment with 100% pure EMU oil. Burns 2007, 33:S148.
42. Politis M.J., Dmytrowich A. Promotion of second intention wound healing by emu oil lotion: comparative results with furasin, polysporin, and cortisone. Plast Reconstr Surg 1998, 102:2404-2407.
43. Lee J.Y., Plakidas A., Lee W.H., Heikkinen A., Chanmugam P., Bray G., et al. Differential modulation of Toll-like receptors by fatty acids preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003, 44:479-486.
44. Kapoor R., Huang Y.-S. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr Pharm Biotechnol 2006, 7:531-534.
45. Vassiliou E.K., Gonzalez A., Garcia C., Tadros J.H., Chakraborty G., Toney J.H. Oleic acid and peanut oil high in oleic acid reverse the inhibitoryeffectof insulin production of the inflammatory cytokine TNF-alphaboth invitro and invivo systems. Lipids Health Dis 2009, 8:25.
46. Carrillo C., Cavia M., Alonso-Torre S. Role of oleic acid in immune system;mechanism of action; a review. Nutr Hosp 2012, 27:978-990.
47. Jäntti J., Nikkari T., Solakivi T., Vapaatalo H., Isomäki H. Evening primrose oil in rheumatoid arthritis: Changes in serum lipids and fatty acids. Ann Rheum Dis 1989, 48:124-127.
48. Ghosh P, Whitehouse M, Dawson M, Turner AG. Anti-inflammatory composition derived from emu oil. Google Patents;1995.
49. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
50. Jamal G.A. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet Med 1994, 11:145-149.
51. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005, 11:90-94.